编号：2014-008 证券代码：300039 证券简称：上海凯宝 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | 活动类别 | □ | 新闻发布会 □路演活动 | | | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | | 德威资本－樊学栋 太平资产－岳雄伟 嘉实基金－董理 东方基金－邱 | | | | 义鹏 中信建投证券－杨扬 张芳 黄健 淡水泉投资－叶智深 郑晓刚 中 | | | | 海基金－俞中华 青溪资产－郝结旺 太平资产－朱云 国泰君安－王超 | | 参与单位名称及 | | 伟 长 ...

证券代码：300039 证券简称：上海凯宝 记录编号：2015-004 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|--------------------------------|----------------------------------------------------------------------| | | | | | | | √特定对象调研 □分析师会议 | | 投资者关 | □媒体采访 □业绩说明会 | | | 系 | □ | 新闻发布会 □路演活动 | | 活动类别 | | □现场参观 □其他 （请文字说明其他活动内容） | | | | | | | 上海申银万国证券 | ---- 周子露 财通基金---赵吉龙 中国国籍证券 --- 李冠一 | | 参与单位 | 华泰长城资本 ---- | 张微 申万宏源研究---罗佳荣 上海益研投资 --- 茆建胜 | | 名称及人 | 上海混沌道然资产—周宇 汇丰晋信 | ---- 段炼炼 唐亮 元大宝来投信 --- 刘家宏 | | 员姓名 | 凯基投资 --- ...

证券代码：300039 证券简称：上海凯宝 记录编号：2017-002 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|-------------------------|------------------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关 | □ | 媒体采访 □业绩说明会 | | 系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | | | | 参与单位 | | | | 名称及人 | 方泉投资 | | | 员姓名 | | | | 时 间 | 2017 年 6 月 13 | 日 下午 14：00 -15 ： 30 | | | | | | 地 点 | 公司二楼会议室 | | | 上市公司 | | | | 接待人员 | 董 秘：穆竟伟 | | | 姓名 | | | | 投资者关 | 1 、公司近期业绩回顾 | | | 系活动主 | | | ...

证券代码：300039 证券简称：上海凯宝 记录编号：2016-002 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|--------------------------------|----------------------------------------------------------------------| | | √ 特定对象调研 □分析师会议 | | | 投资者关 | □ 媒体采访 □业绩说明会 | | | 系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | | | | 参与单位 | | | | 名称及人 | 安信证券、郎晨投资 | | | 员姓名 | | | | 时 间 | 2016 年 11 月 10 | 日 下午 13：30 -15：00 | | | | | | 地 点 | 公司二楼会议室 | | | 上市公司 | | | | 接待人员 | 董 秘：穆竟伟 财务总监：任立旺 | | | 姓名 | | | | 投资者关 | 1 、介绍公司基本情况 ...

证券代码：300039 证券简称：上海凯宝 记录编号：2017-004 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|------------------------|-------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关 | □ | 媒体采访 □业绩说明会 | | 系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | --- | --- | |----------|------------------------------------------------------------------| | | | | 参与单位 | | | 名称及人 | 凯峰资本 | | 员姓名 | | | 时 间 | 2017 年 9 月 25 日 下午 2： 30 -4：00 | | 地 点 | 公司二楼会议室 | | 上市公司 | | | 接待人员 | 董 秘：穆竟伟 证券部：马聪 ...

证券代码：300039 证券简称：上海凯宝 记录编号：2017-003 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|-------------------------|------------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关 | □ | 媒体采访 □业绩说明会 | | 系 | □ | 新闻发布会 □路演活动 | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | | | | 参与单位 | | | | 名称及人 | | 中金公司、财通证券、承珞资本、 | | 员姓名 | | | | 时 间 | 2017 年 8 月 23 | 日 上午 10： 30 -12：00 | | 地 点 | 公司二楼会议室 | | | 上市公司 | | | | 接待人员 | | 董 秘：穆竟伟 证券部：马聪影 | | 姓名 | | | | 投资者关 | | 一、董秘穆竟伟女士简单介绍公司基本情况 | | ...

Financial Performance - The company's revenue for Q3 2022 was ¥259,841,333.60, representing a 1.14% increase year-over-year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥35,835,359.96, up 6.31% compared to the same period last year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥34,405,017.31, reflecting a significant increase of 21.88% year-over-year[7]. - Total operating revenue for the current period reached ¥800,013,064.85, a slight increase from ¥794,949,444.36 in the previous period, representing a growth of approximately 1.34%[30]. - Net profit for the current period was ¥118,044,013.52, compared to ¥115,498,710.67 in the previous period, indicating an increase of approximately 2.14%[30]. - Other comprehensive income after tax for the current period was ¥585,310,000.00, compared to ¥373,137,500.00 in the previous period, reflecting an increase of approximately 56.8%[32]. - The total comprehensive income for the current period was ¥703,354,013.52, compared to ¥488,636,210.67 in the previous period, indicating a growth of about 43.9%[32]. Cash Flow and Investments - The operating cash flow net amount for the year-to-date period increased by 129.99%, totaling ¥236,316,100.08[7]. - Net cash flow from operating activities decreased by 135.05% year-over-year, mainly due to increased investment activities[16]. - Cash inflow from operating activities totaled ¥1,008,773,655.28, up from ¥963,717,206.74, representing an increase of approximately 4.7%[33]. - Cash inflow from investment activities totaled $2.47 billion, compared to $1.46 billion in the prior period, indicating strong investment recovery[36]. - Net cash outflow from investment activities was $197.78 million, a decline from a positive cash flow of $3.72 million previously, suggesting increased investment expenditures[36]. - Cash inflow from the recovery of investments was $2.07 billion, significantly higher than $1.32 billion in the previous period, highlighting effective investment strategies[36]. - The company made cash payments for investments totaling $2.13 billion, compared to $1.31 billion previously, indicating aggressive investment in growth opportunities[36]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,156,931,861.21, a 23.87% increase from the end of the previous year[7]. - The company's total current assets as of September 30, 2022, amount to CNY 2,357,412,713.73, an increase from CNY 2,254,417,970.03 at the beginning of the year[21]. - The total non-current assets increased to CNY 1,799,519,147.48 from CNY 1,101,398,799.74[24]. - The total liabilities increased to ¥460,966,028.56 from ¥310,904,950.64, showing a significant rise of approximately 48.3%[30]. - The total liabilities include short-term borrowings of CNY 81,910,127.65 and accounts payable of CNY 75,015,901.66[24]. Shareholder Information - Shareholders' equity attributable to the parent company was ¥3,696,536,519.48, marking a 21.40% increase compared to the previous year[7]. - The total number of common shareholders at the end of the reporting period is 58,608, with the top ten shareholders holding significant stakes[17]. - The largest shareholder, Mu Jingwei, holds 16.06% of the shares, amounting to 168,029,270 shares[17]. Operational Costs and Expenses - Total operating costs decreased to ¥660,043,298.28 from ¥663,967,428.89, reflecting a reduction of about 0.44%[30]. - Research and development expenses rose to ¥36,092,230.66 from ¥31,986,225.60, marking an increase of about 12.6%[30]. - The company paid $173.05 million to employees, an increase from $162.09 million, reflecting higher operational costs[36]. - Cash outflow related to other operating activities was $370.61 million, down from $408.61 million, showing improved cost management[36]. Government Support - The company received government subsidies amounting to ¥3,159,357.91 during the reporting period[8]. Miscellaneous - The company has not disclosed any new strategies or future outlook in the provided documents[19].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥540,171,731.25, representing a 0.40% increase compared to the same period last year[27]. - The net profit attributable to shareholders for the same period was ¥82,777,022.64, reflecting a 1.21% increase year-on-year[27]. - The net cash flow from operating activities increased significantly by 60.04%, reaching ¥135,594,349.20[27]. - Total assets at the end of the reporting period amounted to ¥4,958,543,477.72, a 47.76% increase from the end of the previous year[27]. - The net assets attributable to shareholders increased by 44.96% to ¥4,413,843,659.52[27]. - Basic earnings per share for the reporting period were ¥0.0791, up 1.15% from the previous year[27]. - The weighted average return on net assets decreased to 2.20%, down 0.93% compared to the same period last year[27]. - Operating costs increased by 15.92% to ¥122,445,859.14 from ¥105,631,636.32 in the previous year[71]. - The gross profit margin for injections is 83.56%, with a year-on-year decrease of 0.48%[75]. Market and Product Development - The company is focused on expanding its market presence and developing new products and technologies[27]. - The company focuses on modern traditional Chinese medicine R&D, production, and sales, with key product lines in respiratory, cardiovascular, and digestive health[36]. - The company has established a comprehensive procurement, R&D, production, and sales system to meet market demands and operational goals[38]. - The company emphasizes a combination of production, learning, and research, collaborating with institutions like Shanghai Jiao Tong University for innovative product development[40]. - The company is advancing the research and development of its main product, Tanreqing, and its series, with ongoing clinical evidence studies[52]. - The company is developing a new 5ml specification for Tanreqing injection, aimed at optimizing product structure[54]. - The company is committed to developing a series of health products supported by its technological accumulation and research in traditional Chinese medicine[62]. - The company is enhancing its market layout in the health sector, aligning with national health strategies[62]. Investment and Funding - The total investment amount for the current period is ¥17,368,421.00, marking a 100% increase compared to the previous year[85]. - The total amount of raised funds is RMB 973.76 million, with RMB 29.7 million invested during the reporting period[87]. - Cumulative investment of raised funds reached RMB 979.05 million by June 30, 2022[92]. - The company plans to use RMB 2,915.91 million of remaining raised funds and interest for the construction of a new R&D building[91]. - The company has invested RMB 13.13 million to acquire 20% equity in Shanghai Yizhong Pharmaceutical Co., Ltd.[91]. - The company has made significant progress in utilizing raised funds for various projects, ensuring effective capital allocation[102]. Risk Management - The company has outlined potential risks and corresponding countermeasures in its management discussion section[5]. - The company acknowledges risks in new drug development, including high investment, long cycles, and potential market changes that could lead to increased costs or project failures[127]. - The company plans to manage R&D risks through various collaborative approaches, optimizing project management, and strengthening the R&D team to ensure successful new drug development[127]. - Raw material prices are subject to fluctuations due to various factors, which can impact profitability; the company will enhance supply chain management to control procurement costs[128]. - The company is closely monitoring industry policy risks, particularly in the pharmaceutical sector, which is heavily influenced by government regulations[125]. Corporate Governance and Compliance - The company has not engaged in derivative investments during the reporting period[117]. - The company has not made any significant asset or equity sales during the reporting period[121]. - The company has no outstanding entrusted loans as of the reporting period[120]. - The company maintained a good integrity status with no unfulfilled court judgments or significant overdue debts[161]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[154]. - There were no violations regarding external guarantees during the reporting period[155]. Social Responsibility - The company actively participated in pandemic prevention efforts, donating approximately CNY 1.2 million worth of products and emergency supplies[51]. - The company donated a total of 150,000 yuan to New Leaf Village and 50,000 yuan to the Shanghai Bay Tourism Area Charity Fund during the reporting period[149]. - The company has not experienced any administrative penalties related to environmental issues during the reporting period[149]. Shareholder Information - The total number of shares before the change was 1,046,000,000, with a 100% ownership ratio[192]. - The largest shareholder, Mu Jingwei, holds 16.06% of the shares, totaling 168,029,270 shares[198]. - The company has a total of 64,324 shareholders at the end of the reporting period[195].

Financial Performance - The company's revenue for Q1 2022 was CNY 343,817,802.76, representing a 1.15% increase compared to CNY 339,907,427.57 in the same period last year[4] - Net profit attributable to shareholders was CNY 57,636,350.93, a 0.70% increase from CNY 57,237,236.12 year-on-year[4] - Total operating revenue for Q1 2022 was CNY 343,817,802.76, a slight increase from CNY 339,907,427.57 in Q1 2021[29] - Net profit for Q1 2022 was CNY 57,142,663.02, showing a marginal decrease from CNY 57,237,236.12 in Q1 2021[32] - Total comprehensive income attributable to the parent company's owners was ¥165,979,475.93, compared to ¥57,237,236.12 in the previous period, indicating significant growth[35] Cash Flow - The net cash flow from operating activities increased by 514.45%, reaching CNY 87,056,121.17, compared to a negative cash flow of CNY -21,005,200.21 in the previous year[4] - Cash inflow from operating activities totaled ¥427,893,178.34, up from ¥325,874,682.61 year-over-year[39] - Cash outflow for operating activities was ¥340,837,057.17, slightly decreased from ¥346,879,882.82 in the previous period[39] - The company reported a net increase in cash and cash equivalents of ¥12,081,417.09, contrasting with a decrease of -¥33,917,259.71 in the previous period[42] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,622,340,110.74, up 7.94% from CNY 3,355,816,769.77 at the end of the previous year[4] - The company's total current assets increased to approximately 2.39 billion yuan, up from 2.25 billion yuan at the beginning of the year, reflecting a growth of about 5.5%[22] - Total liabilities rose to CNY 411,942,503.59, up from CNY 310,904,950.64 in the previous year[28] - The company's total liabilities increased, with accounts payable rising by 58.59% due to increased material costs[9] Shareholder Information - The total number of common shareholders at the end of the reporting period is 83,262, with the largest shareholder, Mu Jingwei, holding 16.06% of shares, equating to 168,029,270 shares[14] - The total number of restricted shares at the end of the reporting period is 129,441,631, with no new restrictions added during the period[18] Research and Development - Research and development expenses decreased by 40.86% compared to the previous year, reflecting a focus on project-based investment[10] - Research and development expenses for Q1 2022 were CNY 10,017,656.02, down from CNY 16,939,440.85 in Q1 2021[29] Investment Activities - The company reported a 63.01% decrease in investment income compared to the previous year, primarily due to reduced returns from bank wealth management products[10] - The company’s subsidiary, Shanghai Kaibao Equity Investment Co., Ltd., increased its investment in Chongqing Jize Biotechnology Co., Ltd. to hold 33% of its registered capital, focusing on the development of new food raw materials[19] - Total cash inflow from investment activities was ¥686,319,148.60, an increase from ¥558,424,293.00 year-over-year[39] Other Financial Metrics - The company's weighted average return on equity increased to 5.31%, up 3.11 percentage points from 2.20% in the same period last year[4] - The company received government subsidies amounting to CNY 1,535,647.80 during the reporting period[5] - The company reported a tax expense of CNY 11,338,642.90 for Q1 2022, compared to CNY 10,860,538.69 in the same period last year[32] - Other comprehensive income after tax for Q1 2022 was CNY 108,343,125.00, all attributable to the parent company's shareholders[32]

Financial Performance - The company reported a total revenue of RMB 1,046 million for the year 2021, representing a year-on-year increase of 15% compared to 2020[6]. - The net profit attributable to shareholders was RMB 150 million, which is a 10% increase from the previous year[6]. - The company's operating revenue for 2021 was ¥1,100,578,391.34, representing a 21.21% increase compared to ¥908,008,861.43 in 2020[25]. - The net profit attributable to shareholders for 2021 was ¥140,113,625.43, a 32.03% increase from ¥106,122,746.60 in 2020[25]. - The net profit after deducting non-recurring gains and losses was ¥125,934,898.50, up 31.63% from ¥95,675,418.53 in the previous year[25]. - The company's cash flow from operating activities decreased by 49.70% to ¥126,078,156.45 from ¥250,649,879.39 in 2020[25]. - The total assets at the end of 2021 were ¥3,355,816,769.77, an increase of 16.63% from ¥2,877,284,200.91 at the end of 2020[25]. - The net assets attributable to shareholders at the end of 2021 were ¥3,044,914,136.88, an 18.10% increase from ¥2,578,324,384.13 at the end of 2020[25]. - The basic earnings per share for 2021 was ¥0.1340, reflecting a 32.02% increase from ¥0.1015 in 2020[25]. - The weighted average return on equity for 2021 was 17.71%, significantly up from 4.05% in 2020[25]. Market Expansion and Product Development - The company plans to distribute a cash dividend of RMB 0.50 per 10 shares, totaling approximately RMB 52.3 million[6]. - The company is focusing on expanding its product line, with plans to launch three new drugs in 2022, targeting a market size of RMB 1 billion[6]. - User data indicates a 20% increase in the number of active users of the company's products, reaching 1.2 million by the end of 2021[6]. - Market expansion efforts include entering two new provinces in China, aiming for a 25% increase in market share by the end of 2022[6]. - Future guidance estimates a revenue growth of 18% for 2022, driven by new product launches and market expansion[6]. - The company is actively seeking new product introductions and acquisitions to expand its product line by leveraging research institutions' resources[154]. - The company is focusing on optimizing its product structure through various new drug research projects, including "痰热清" injection and oral solutions[61]. - The company is enhancing its R&D capabilities and accelerating the development of new products, aiming for a diversified product lineup[154]. Research and Development - The company has allocated RMB 100 million for research and development in new technologies and products for the upcoming year[6]. - The company has formed a joint R&D center with Shanghai Jiao Tong University to enhance collaboration in technology development and production[46]. - The company emphasizes innovation and has established a modernized R&D building to support new product development and attract research talent[51]. - The company obtained 4 invention patents, 5 design patents, and 11 utility model patents during the reporting period, enhancing its intellectual property protection[59]. - The company is conducting clinical research on "痰热清" for treating COVID-19, which has received recognition as an outstanding project in Shanghai[56]. - The company is conducting Phase III clinical trials for the new drug Dinggui Oil Soft Capsule, aimed at treating irritable bowel syndrome[91]. - The company is also in Phase III clinical trials for the new drug Phlegm Heat Clear Oral Liquid, targeting respiratory diseases[94]. Risk Management and Challenges - The company has identified potential risks in regulatory changes and market competition, with strategies in place to mitigate these risks[6]. - The company faces industry risks due to government policies affecting the pharmaceutical sector, which may impact operational performance[153]. - New drug development carries high investment, long cycles, and significant risks, which could adversely affect profitability and future growth[154]. - The ongoing COVID-19 pandemic continues to pose uncertainties, but the company is working to minimize its impact on operations and ensure the availability of pandemic-related medications[155]. Corporate Governance and Management - The company has a dedicated investor relations management team to enhance communication with investors through various channels[175]. - The company adheres to legal and regulatory requirements, ensuring no significant discrepancies in corporate governance practices[175]. - The company has established a clear organizational structure with independent operational departments, ensuring no mixed operations with controlling shareholders[179]. - The management team includes professionals with qualifications such as CPA and advanced degrees, indicating a robust financial oversight[196]. - The company has a strong management team with diverse backgrounds in pharmaceuticals, finance, and law, enhancing its operational capabilities[198]. Sales and Marketing - The sales model primarily utilizes a specialized clinical academic promotion approach, supported by a well-trained sales team across various regions in China[53]. - The company is expanding its market presence by leveraging academic marketing strategies and conducting clinical re-evaluations of its products[71]. - The company will continue to promote its products through academic channels and enhance brand influence and product awareness[151]. Subsidiaries and Partnerships - The subsidiary, Kaibao Health, focuses on product development and market promotion in the health technology sector, aiming to leverage traditional Chinese medicine's unique advantages[46]. - The company has successfully diversified its operations through its subsidiary Shunjie Pharmaceutical, which has obtained necessary licenses for drug and medical device sales[46]. - The company has established partnerships with institutions like Shanghai University of Traditional Chinese Medicine to enhance R&D capabilities[72].